An Epigenetic Regulator Screen Identifies Novel Targets That Sensitize MLL-Rearranged Leukemia to DOT1L Inhibition

Mixed Lineage Leukemia gene rearrangements ( MLL -r) account for nearly 10% of human acute leukemia cases and are generally associated with poor prognosis. Previous studies have revealed an essential role of the histone H3K79 methyltransferase Disruptor of Telomeric Silencing-1 Like ( DOT1L) in MLL -r leukemogenesis. Our recent report ( Chen et al. 2015 Nature Medicine ) further identified a role for histone acetylation in DOT1Ldependent gene expression driven by MLL -fusion proteins including MEIS1 and HOXA cluster genes. A first-in-human Phase I clinical trial demonstrated clinical activity of DOT1Linhibition in MLL -r leukemia patients, thus providing a potential opportunity for treating these malignant diseases. Nevertheless, the incomplete silencing of the leukemic program by only targeting DOT1Lmotivates the need for additional and perhaps combinational approaches to improve therapies against MLL -r leukemias. To enhance the efficacy of DOT1Linhibition, we sought to identify genes whose suppression would synergize with the DOT1Linhibitors to suppress the proliferation of mouse bone marrow progenitors transformed with MLL-AF9. We conducted a pooled RNAi screen using a customized library composed of 2,252 shRNA targeting 468 epigenetic regulators ( i.e. writers, readers, and erasers of chromatin modifications; Fig 1). The integrated shRNA sequences were assessed using high-throughput sequencing. By comparing the change in frequency of each shRNA construct cultured in control vs. an IC 50 DOT1Linhibitor EPZ4777, we identified several candidate modulators of DOT1Ldependency, which had multiple shRNAs selectivity depleted only in the DOT1Lsuppressed condition. Notably, using a network correlation study, we found that one of the top candidate genes Plant Homeodomain Finger Protein 20 ( PHF20 ) is highly associated with histone acetylation in the mammalian epigenome. Knockdown of PHF20 drastically increased the sensitivity of MLL-AF9 leukemic blasts to DOT1Linhibitors through enhanced myeloid differentiation and reduced cell proliferation, colony formation, and re-plating capacity. Similar phenotypes were also observed in PHF20-deficient MLL-AF9 cells generated by CRISPR/Cas9-mediated gene knockout. PHF20 is an epigenetic adaptor protein that has no predicted enzymatic activity. To investigate the role of PHF20, we conducted a CRISPR functional domain screen and identified the requirement of the chromatin reader domains in PHF20, including the Tudor domainsand the PHD-finger, in supporting the survival of MLL -r leukemic cells upon DOT1Linhibition. We also performed RNA-seq and found that suppression of PHF20 facilitated the silencing of the MLL-AF9 leukemic program induced by DOT1Linhibitor treatment. Chromatin immunoprecipitation and sequencing (ChIP-seq) analyses validated that PHF20 contributes to the maintenance of histone acetylation including H3K9ac and H4K16ac at MLL-AF9 target loci. In line with the profound loss of histone acetylation at MLL-AF9 target loci in PHF20-depleted cells, we found that knockdown of a known PHF20 interacting partner KAT8 (a histone acetyltransferase; also known as MOF or MYST1) phenocopiesthe effects observed in PHF20-knockdown cells. Finally, we showed that pharmacological inhibition of DOT1Land KAT8 synergistically suppresses the proliferation and survival of MLL-AF9 leukemic cells. These data collectively highlight the involvement of a novel DOT1L-PHF20-KAT8 axis in mammalian gene regulation and MLL -r leukemogenesis. In summary, our studies show that MLL -rearrangements may drive leukemic transformation by coordinating an epigenetic network involving several histone modifications associated with gene transcription ( e.g. H3K79 methylation and H3K9/H4K16 acetylation). Our results also suggest that simultaneous targeting of multiple components of this epigenetic feed-forward loop including DOT1Land PHF20/KAT8 may provide a novel and more effective approach against MLL -r leukemia. Disclosures Bradner: Novartis Institutes for BioMedical Research: Employment. Armstrong: Epizyme, Inc: Consultancy; Vitae Pharmaceuticals: Consultancy; ImagoBiosciences: Consultancy; Janssen Pharmaceutical: Consultancy.